[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"small-cell-lung-cancer-sclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:small-cell-lung-cancer-sclc":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,61,84,108,143,188,212,233,275,307,341,364,391,419,458,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100321141","phase-1-a-study-of-mevrometostat-for-treatment-of-relapsedrefractory-sclc-castration-resistant-prostate-cancer-and-follicular-lymphoma-100321141",false,"NCT03460977","A Study of Mevrometostat for Treatment of Relapsed\u002FRefractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma","A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED\u002FREFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)","Part 1 and Part 2 (Closed for enrollment).\n\nPart 3 Key Inclusion Criteria:\n\n* Histological or cytological diagnosis of castration resistant prostate cancer.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.\n* Adequate bone marrow, renal, and liver function\n\nPart 3 Key Exclusion Criteria:\n\n* Prior irradiation to \\>25% of the bone marrow.\n* QTcF interval \\>480 msec at screening.\n* Hypertension that cannot be controlled by medications (\\>150\u002F90 mmHg despite optimal medical therapy).\n* Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)\n* Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.\n* Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4\u002F5 inducers or inhibitors\n* Prior enzalutamide within the last 4 weeks\n* DDI SUBSTUDY:\n* history of CHF or evidence of ventricular dysfunction\n* fructose intolerance\n* coadministration of CYP3A4 substrates","ALL","18 Years",{"count":19,"type":20},453,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed\u002F Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.\n\nPart 3, which is open for enrollment is seeking men who:\n\n* have Castration Resistant Prostate Cancer (CRPC) and\n* have previously received treatment for CRPC and have progressed from the last treatment\n\nAll participants in Part 3 of this study will receive mevrometostat and\u002F or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).\n\nIn the assessment phase:\n\n* participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.\n* participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and\u002For itraconazole 1 time a day based on a present schedule.\n* participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and\u002For itraconazole 1 time a day based on a present schedule.\n\nAfter completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.\n\nThe study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.",[26,27,28],"Metastatic Castration Resistant Prostate Cancer (mCRPC)","Small Cell Lung Cancer (SCLC)","Follicular Lymphoma (FL)",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47],"EZH2","enhancer of zeste homolog 2","castrate resistant prostate cancer","prostatecancer-study.com","mCRPC","efficacy","safety","pharmacokinetics","pharmacodynamics","dose escalation","dose expansion","open-label","small cell lung cancer","SCLC","follicular lymphoma","FL","relapsed","refractory","RECRUITING","2026-06-29",{"date":51,"type":52},"2026-07-01","ACTUAL",{"date":54,"type":52},"2018-04-17",{"date":56,"type":20},"2029-07-07",{"name":58,"class":59},"Pfizer","INDUSTRY",83,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":21,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100604426","phase-2-adjuvant-chemotherapy-and-immunotherapy-for-completely-resected-small-cell-lung-cancer-100604426","NCT07149363","Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Body weight \\>30 kg.\n* Must have a life expectancy of at least 12 weeks.\n* Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.\n* Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.\n* Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.\n* No prior systemic therapies, for small cell lung cancer.\n* Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* Patients who are receiving any other investigational agents.\n* Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.\n* Prior treatment with durvalumab.\n* History of another primary malignancy except for:\n\n  * Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Superficial bladder cancer without active disease after treatment.\n  * Low grade prostate cancer without indication for active treatment.\n  * Adequately treated carcinoma in situ without evidence of disease.\n* Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.\n* Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.\n* Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.",{"count":68,"type":20},65,[70],"PHASE2","This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).",[27],"2026-06-25",{"date":75,"type":52},"2026-06-26",{"date":77,"type":52},"2026-02-12",{"date":79,"type":20},"2031-02",{"name":81,"class":82},"Alliance Foundation Trials, LLC.","OTHER",3,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100629272","phase-3-dareon---lung-1-a-study-in-people-with-advanced-small-cell-lung-cancer-to-compare-obrixtamig-plus-atezolizumab-carboplatin-and-etoposide-treatment-with-standard-chemotherapy-100629272","NCT07472517","DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","DAREON ® -Lung-1: A Phase III Multi-center, Open-label, Randomised Trial of Intravenous Obrixtamig in Combination With Atezolizumab, Carboplatin, and Etoposide vs. Atezolizumab, Carboplatin, and Etoposide as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer","Inclusion Criteria :\n\n1. Patients with histologically confirmed Extensive-stage Small Cell Lung Cancer (ES-SCLC)\n2. Patients without any previous systematic anti-cancer treatment for ES-SCLC. Patients who received previous systematic anti-cancer treatment during limited stage are eligible if the treatment has been completed more than 6 months before the diagnosis of ES-SCLC.\n3. Adequate archival formalin-fixed paraffin-embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status and other biomarkers. The central laboratory investigational VENTANA DLL3 (SP347) RxDx test result must be available prior to randomisation.\n4. Patients with asymptomatic brain metastasis are eligible if they meet one of the following criteria:\n\n   * Treatment for brain metastases (e.g. whole brain radiation therapy, stereotactic radiotherapy, or radiosurgery) completed at least 14 days prior to randomisation and neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 7 days prior to randomisation\n   * Untreated brain metastases that do not require treatment and are neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 28 days prior to randomisation\n5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1\n6. Eligible for continuing carboplatin + etoposide + atezolizumab regimen as first-line Standard of care (SoC) treatment within 28 days after the start of the initial cycle of standard therapy\n7. Eligible to receive treatment with full dose of atezolizumab, carboplatin, and etoposide as first-line SoC treatment, in accordance with the approved Summary of Product Characteristics if provided centrally or approved local product label if provided by the trial site Further inclusion criteria apply.\n\nExclusion Criteria :\n\n1. Presence of leptomeningeal disease and\u002For carcinomatous meningitis\n2. Previous treatment targeting DLL3 (e.g. T cell engagers (TcEs), cell therapies, antibody-drug conjugates, or radiopharmaceuticals)\n3. Radiotherapy of any anatomical sites within 14 days prior to randomisation\n4. Persistent toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 (except for alopecia, asthenia\u002Ffatigue, amenorrhea\u002Fmenstrual disorders, CTCAE Grade 2 peripheral neuropathy, and CTCAE Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks prior to randomisation, per investigator judgment)\n5. Patient with active autoimmune disease or a documented history of autoimmune disease that requires systemic treatment (e.g. glucocorticoids or immunosuppressive drugs). Patients with vitiligo, resolved childhood asthma\u002Fatopy, alopecia, or any chronic skin condition that does not require systemic therapy, patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and\u002For controlled Type 1 diabetes mellitus on a stable insulin regimen may be included if in the opinion of the investigator it is appropriate and safe to do so.\n\nFurther exclusion criteria apply.",{"count":92,"type":20},670,[94],"PHASE3","This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3.\n\nParticipants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein.\n\nParticipants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.",[27,97],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","2026-06-22",{"date":100,"type":52},"2026-06-23",{"date":102,"type":52},"2026-04-13",{"date":104,"type":20},"2029-07-30",{"name":106,"class":59},"Boehringer Ingelheim",237,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":21,"phases":117,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100642818","phase-1-the-0504-in-patients-with-solid-tumors-100642818","NCT07646106","THE-0504 in Patients With Solid Tumors","NANOFER-THE-0504: A Trial to Assess the Safety and Tolerability of an Investigational Drug THE-0504 for Patients With Solid Tumors","Inclusion Criteria:\n\nPatients will be enrolled in the study if they meet all the following criteria:\n\n1. written informed consent obtained;\n2. both gender adult (≥ 18 years) patients;\n3. diagnosis of solid tumor. Preferably, but non-limited, tumor types are the following: Small Cell Lung Cancer (SCLC), Colorectal Carcinoma (CRC), Pancreas Adenocarcinoma (PaAdCa), Gastric Cancer (GC) and Triple Negative Breast Cancer (TNBrCa);\n4. measurable metastatic disease or locally advanced unresectable tumors;\n5. have exhausted all EMA-approved treatment options;\n6. ECOG Performance Status graded as 0 or 1;\n7. patients able to understand the full nature and the purpose of the trial, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire trial (ability to attend all the planned trial visits according to the time limits included) based on Investigator's judgement;\n8. adequate liver function as assessed by following laboratory tests to be conducted within 28 days before the first dose of study treatment:\n\n   * Total bilirubin ≤ 1.5 × ULN (or ≤ 3 X ULN for patients with documented Gilbert-Meulengracht Syndrome, or for patients with hyperbilirubinemia considered due to liver metastasis).\n   * Aspartate transaminase and alanine transaminase ≤ 2.5 × ULN (or ≤ 5 × ULN if due to liver involvement by tumor);\n9. adequate kidney function as assessed by following laboratory test to be conducted within 28 days before the first dose of study treatment:\n\n   • Estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin per 1.73 m2 according to the CKD-EPI formula.\n10. adequate bone marrow function as defined as:\n\n    * Hgb ≥ 9 g\u002FdL\n    * ANC ≥1.5x109\u002FL\n    * PLT≥100.0 x109\u002FL\n11. Female patients of childbearing potential and male patients who are sexually active with women of childbearing potential will have to mandatorily use an appropriate method of contraception, according to the definition of Note 3 of ICH M3 Guideline, for the entire duration of the trial and for a minimum of 12 months after last administration of the IMP.\n\nExclusion Criteria:\n\nPatients will not be enrolled if they meet any of the following criteria:\n\n1. pregnant (as determined by a blood pregnancy test at the screening visit) or lactating women;\n2. male patients who are willing to father children during the trial or in the 12 months after the end of IMP administration;\n3. additional malignancy in the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy;\n4. have any unresolved toxicity of Grade ≥ 2 from previous anti-cancer treatment, except for alopecia and skin pigmentation. Patients with chronic, but stable Grade 2 toxicities may be allowed to enrol after agreement between the Investigator and Sponsor;\n5. ECOG Performance Status \\> 2;\n6. had not tolerated previously administered Top1 inhibitor treatments;\n7. known active CNS metastatic disease (patients with CNS metastases that are treated with radiotherapy and are stable for at least 28 days before study treatment start could be considered eligible);\n8. serious concurrent illness;\n9. Hgb \\\u003C 9 g\u002FdL;\n10. Transfusion dependent anemia with transfusion dependency of ≥3 months;\n11. Clinically significant iron metabolism disorders (e.g., sickle cell anemia) or use of iron chelators treatments;\n12. Iron overload, hereditary hemochromatosis and similar;\n13. Moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment;\n14. Prolonged QTc interval;\n15. Multiple Sclerosis (MS) or other demyelinating disease, Eaton-Lambert syndrome, history of haemorrhagic or ischemic stroke within the last 6 months, or alcoholic liver disease;\n16. Non-healing wound(s), except for ulcerative lesions caused by the underlying neoplasm;\n17. History of severe allergic or anaphylactic reactions to previous protein-based therapy;\n18. Currently receiving anticoagulation therapy with warfarin;\n19. Known history of HIV infection, unless all the following are applicable:\n\n    * receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥ 3 months prior to the planned first study intervention;\n    * CD4 T-cell count \\> 350 cells\u002FμL\n    * CD4 T-cell nadir (lowest historical count) \\> 350 cells\u002FμL, and • viral load confirmed as \\\u003C 50 copies\u002FmL.\n20. HBV infection, unless on stable anti-viral therapy for \\> 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable; and HCV infection, unless the participant has received curative treatment and viral load was confirmed as undetectable;\n21. Known autoimmune disease, uncontrolled diabetes, vitiligo, or stable thyroid disease;\n22. Patients on chronic (more than 10 days) administration of systemic, high-dose corticosteroids (≥4 mg Dexamethasone or equivalent), not amenable for reduction or suspension;\n23. Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations;\n24. History of drugs and\u002For alcohol abuse;\n25. Patients considered to be unsuitable to participate, in the Investigator's opinion, for any other reason (e.g. consequences of previous medical and\u002For surgical procedures or other medical or ethical reasons);\n26. Planned relocation during the study, which would make impossible to attend the scheduled visits and follow-ups;\n27. Concomitant participation in other clinical trials or participation in the evaluation of any investigational drugs\u002Fproducts up to 4 weeks before this trial (in any case, enrolment procedure should start only after the complete washout of the drugs\u002Fproducts under investigation\\*\\*); or previous participation in the same trial or planned to receive other investigational products during the study.",{"count":116,"type":20},30,[23],"Single-centre, open-label, dose escalation phase I clinical trial, designed to evaluate mainly the safety and tolerability of the antitumor drug THE-0504 in patients with different types of solid tumors.",[27,120,121,122,123],"Colorectal Carcinoma (CRC)","Gastric Cancer (GC)","Triple -Negative Breast Cancer","Pancreas Adenocarcinoma",[125,126,127,128,129,130,131,132],"THE-0504","Solid tumors","Cancer","Single-centre","Thena Biotech","Italy","Phase 1","Europe","2026-06-09",{"date":135,"type":52},"2026-06-12",{"date":137,"type":52},"2024-11-13",{"date":139,"type":20},"2027-05-01",{"name":141,"class":59},"Thena Biotech S.r.l.",1,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":166,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":83},"100632708","phase-1-dose-determining-study-of-exs74539-rec-4539-in-participants-with-select-solid-tumors-100632708","NCT07517198","Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors","A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Histologically confirmed diagnosis of the following solid tumors:\n\n  * SCLC\n  * High grade neuroendocrine or small cell carcinomas of non-lung origin\n  * Non-small cell lung cancer \\[NSCLC\\]\n  * Prostate cancer\n  * Ovarian cancer\n  * Renal carcinoma \\[clear and non-clear cell\\]\n  * Head and neck squamous cell carcinoma\n  * Hepatic cancer\n  * Gastric cancer\n  * Triple-negative breast cancer \\[TNBC\\]\n* Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.\n\nKey Exclusion Criteria:\n\n* Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study.\n* Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases.\n* Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \\\u003C7 days of the first scheduled dose of the study treatment.\n* Significant cardiac abnormalities.\n* Major surgery within 28 days prior to the start of study treatment.\n\nNote: Other protocol-defined inclusion and exclusion criteria may apply.",{"count":151,"type":20},40,[23],"The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.",[155,27,156,157,158,159,160,161,162,163,164,165],"Solid Tumor","High Grade Neuroendocrine Cancer","Small Cell Carcinomas of Non-lung Origin","Non-small Cell Lung Cancer (NSCLC)","Prostate Cancer","Ovarian Cancer","Renal Carcinoma (Clear and Non-clear Cell)","Head and Neck Squamous Cell Carcinoma (HNSCC)","Hepatic Cancer","Gastric Cancer","Triple-negative Breast Cancer (TNBC)",[167,27,168,169,170,171,172,173,174,175,176,177,178,179,180],"Solid Tumors","High grade neuroendocrine cancer","Small cell carcinomas of non-lung origin","Non-small cell lung cancer (NSCLC)","Prostate cancer","Ovarian cancer","Renal carcinoma (clear and non-clear cell)","Head and neck squamous cell carcinoma (HNSCC)","Hepatic cancer","Gastric cancer","Triple-negative breast cancer (TNBC)","LSD1 inhibitor","EXS74539","REC-4539",{"date":182,"type":52},"2026-06-10",{"date":102,"type":52},{"date":185,"type":20},"2029-03",{"name":187,"class":59},"Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},"100610393","phase-2-symbiotic-lung-04-a-study-to-learn-about-the-study-medicine-called-pf-08634404-in-combination-with-chemotherapy-in-adult-participants-with-extensive-stage-small-cell-lung-cancer-100610393","NCT07226999","Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer","A GLOBAL PHASE 2\u002F3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER","Inclusion Criteria:\n\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).\n* Participants have not received systemic therapy (chemotherapy, radiotherapy, chemoradiation) for ES-SCLC.\n* Treatment-free for at least 6 months since last chemo\u002Fradiotherapy, among those treated (with curative intent) with prior chemo\u002Fradiotherapy for limited-stage SCLC\n* Have at least one measurable lesion as the targeted lesion based on RECIST V1.1.\n* Eastern Cooperative Oncology Group performance status of 0 or 1.\n* Adequate organ function\n\nExclusion Criteria:\n\n* known active CNS lesions, including brainstem, meningeal, or spinal cord metastases or compression\n* Leptomeningeal disease\n* Clinically significant risk of hemorrhage or fistula\n* history of another malignancy within 3 years\n* active autoimmune diseases requiring systemic treatment within the past 2 years",{"count":196,"type":20},550,[70,94],"This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body.\n\nTo join the study, participants must meet the following conditions:\n\n* Be 18 years or older.\n* Have extensive-stage small cell lung cancer confirmed by lab tests.\n* Have not received chemotherapy or radiation for this type of lung cancer.\n* Be in good physical condition and have healthy organs based on medical tests.\n\nThe study has two parts:\n\n* In the first part, researchers will check how safe the study medicine is and how well people tolerate it when given with chemotherapy.\n* In the second part, they will compare study medicine plus chemotherapy to another approved treatment (atezolizumab plus chemotherapy) to see which works better.\n\nParticipants will receive the treatment through IV infusions (medicine given directly into a vein). The treatment will be given in repeated time periods called cycles. Some participants will continue receiving the study medicine alone after the initial treatment.",[27],[42,201,202],"extensive stage small cell lung cancer","first-line","2026-06-03",{"date":205,"type":52},"2026-06-04",{"date":207,"type":52},"2025-12-09",{"date":209,"type":20},"2034-03-11",{"name":58,"class":59},43,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":142},"100635925","phase-1-safety-and-preliminary-activity-of-bi115-in-advanced-sclc-100635925","NCT07559019","Safety and Preliminary Activity of BI115 in Advanced SCLC","Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants With Advanced Small Cell Lung Cancer","Inclusion Criteria：\n\n1. Participants must be able to understand and sign the written informed consent form for participation in this trial, including all evaluations and procedures specified in this protocol.\n2. Male or female participants aged ≥18 years and ≤75 years.\n3. Participants with histologically or cytologically confirmed advanced small cell lung cancer.\n4. At least one measurable lesion according to RECIST V1.1 within 28 days prior to the first dose of IBI115.\n5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.\n6. Expected survival period ≥12 weeks.\n7. Adequate bone marrow and organ function confirmed during the screening period.\n\nExclusion Criteria：\n\n1. Concurrent participation in another interventional clinical study, except for observational non-interventional studies or being in the survival follow-up phase of an interventional study.\n2. Administration of a live vaccine within 4 weeks prior to the first dose of the study drug or a cancer vaccine within 3 months prior, or planning to receive any live vaccine during the study period.\n3. Adverse reactions from prior anti-tumor therapy that have not resolved to CTCAE v6.0 Grade 0, Grade 1, or baseline levels by the time of the first dose of the study drug.\n4. Known hypersensitivity or intolerance to IBI115, sintilimab, or any of their excipients.","75 Years",{"count":221,"type":20},150,[23],"This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer",[27],"2026-06-02",{"date":205,"type":52},{"date":228,"type":52},"2026-05-21",{"date":230,"type":20},"2030-03-30",{"name":232,"class":59},"Innovent Biologics (Suzhou) Co. Ltd.",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":251,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":274},"100614352","phase-1-study-of-212pbpb-dotam-mam279-212pbpb-mp0712-in-patients-with-small-cell-lung-cancer-and-other-dll3-expressing-solid-tumors-100614352","NCT07278479","Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","A Phase 1\u002F2a Study to Assess Safety, Tolerability, and Efficacy of [212Pb]Pb-DOTAM-MAM279 in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","Key Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung\n\n  * SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or\n  * LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:\n  * Gastroenteropancreatic NECs (GEPNEC), or\n  * Cervical NECs, or\n  * Bladder NECs, or\n  * other epNECs with previously confirmed DLL3 expression by IHC.\n  * Patients with prior DLL3-targeted therapy are allowed.\n* For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by \\[203Pb\\]Pb-DOTAM-MAM279 SPECT\u002FCT\n* Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy\n* At least one measurable disease per RECIST v1.1.\n* Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening\n* Adequate blood counts: Hemoglobin ≥9 g\u002FdL; Absolute neutrophil count (ANC) ≥1.5 × 10\\^9\u002FL; Platelets ≥100 × 10\\^9\u002FL; White blood cells (WBC) ≥2.5 x 10\\^9\u002FL;\n* Adequate hepatic function\n* Adequate renal function: Calculated glomerular filtration rate (GFR) \\>60mL\u002Fmin (using Cockroft-Gault formula).\n* Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.\n\nKey Exclusion Criteria:\n\n* Uncontrolled intercurrent illness\n* Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).\n* Active clinically significant cardiac disease\n* Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n* History of other malignancy within the past 2 years with exceptions.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":241,"type":20},138,[23,70],"The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \\[212Pb\\]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.",[245,246,247,27,248,249,250],"Large Cell Neuroendocrine Carcinoma","Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)","Gastroenteropancreatic NEC (GEP NEC)","NEC of the Bladder","Other DLL3 Expressing epNEC",[252,253,254,255,256,257,43,258,259,260,261,262,263,264,265],"DARPin","Alpha Emitter","Pb203","Pb212","DLL3","Radioligand therapy (RLT)","Neuroendocrine cancer","[203Pb]Pb-DOTAM-MAM279","[212Pb]Pb-DOTAM-MAM279","EP-NEC","Lead 212","Lead 203","203Pb","212Pb",{"date":267,"type":52},"2026-05-22",{"date":269,"type":52},"2026-05-18",{"date":271,"type":20},"2032-09",{"name":273,"class":59},"Molecular Partners AG",5,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":306},"100632210","real-world-data-on-the-treatment-of-lung-cancer-patients-with-the-immune-checkpoint-inhibitor-tislelizumab-100632210","NCT07510724","Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab","Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab - the ReWoLuTe Study","IKF-ReWoLuTe","Inclusion criteria:\n\n* Patient has a histologically confirmed resectable Non-small cell lung cancer in stage II-IIIA with high risk of recurrence according to the 8th edition of the following AJCC staging criteria and is eligible for an R0 resection with curative intent and treatment with Tislelizumab in neoadjuvant and adjuvant setting:\n\n  1. Tumor size \\>4cm; or tumors of any size with either N1 or N2 status\n  2. Tumors invading thoracic structures (directly into the visceral pleura, parietal pleura, chest wall, main bronchus, phrenic nerve, mediastinal pleura, parietal pericardium)\n  3. Tumors \\>4cm that cause obstructive atelectasis extending to the hilum and involving parts of the lung, the entire lung or a main bronchus, regardless of the distance to the carina, or that invade the visceral pleura (PL1 or PL2)\n  4. Tumors with one or more separate nodules in the same lobe as the primary lung carcinoma.\n\n     OR\n\n     Patient has a histologically confirmed locally advanced or metastatic lung carcinoma of one of the following subtypes and is eligible for treatment with Tislelizumab in an approved indication:\n  5. NSCLC, squamous type, and the patient is not a candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,\n  6. NSCLC, non-squamous type with PD-L1 expression on ≥50% of tumor cells and without EGFR- or ALK-positive mutations, and patient is not candidate for surgical resection or platinum-based chemoradiation and did not receive prior treatment in palliative setting,\n  7. NSCLC, squamous or non-squamous type, and the patient already received prior platinum-based therapy and, if with EGFR- or ALK-positive mutations, also has received targeted therapies,\n  8. SCLC, extensive-stage, and the patient has not received prior treatment in palliative setting.\n* A decision for treatment with an authorized Tislelizumab-based regimen has been made by the treating physician before enrolling into ReWoLuTe study.\n\nNOTE:\n\nPatients who have already received 1-2 cycles of therapy are still eligible for enrollment into the NIS. Patients who intended to be treated in the curative setting and had to switch before the start of an adjuvant treatment to the palliative setting or BSC (e.g. due to progress or other reasons), will not be excluded from study.\n\nExclusion criteria:\n\n* The patient has not provided signed informed consent.\n* The patient is under 18 years of age at the time of providing signed informed consent.\n* The patient is unable to fully comprehend the implications of study participation.",{"count":284,"type":20},240,"OBSERVATIONAL","The ReWoLuTe study (IKF091) is a prospective, multi-center, observational cohort study conducted in Germany and Austria to collect real-world data on the use of Tislelizumab-based therapies in patients with lung cancer. The study aims to evaluate the overall survival, treatment patterns, safety, and health-related quality of life of patients receiving Tislelizumab in everyday clinical practice.",[27,288,289],"Non-Small Cell Lung Cancer (NSCLC)","Lung Cancer (Diagnosis)",[291,292,293,294,295,296],"Lung Cancer","Tislelizumab-based therapy","real-world data on tislelizumab treated patients","resectable NSCLC (perioperative setting)","locally advanced or metastatic NSCLC (1st\u002F2nd line)","extensive-stage SCLC (1st line)","2026-03-30",{"date":299,"type":52},"2026-04-03",{"date":301,"type":52},"2025-12-23",{"date":303,"type":20},"2033-01-23",{"name":305,"class":82},"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest",2,{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":315,"targetDuration":4,"studyType":21,"phases":317,"briefSummary":318,"conditions":319,"keywords":322,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":142},"100629864","phase-1-adaptive-phase-12-study-of-dual-target-car-nk-cells-in-relapsedrefractory-small-cell-lung-cancer-sclc-100629864","NCT07480213","Adaptive Phase 1\u002F2 Study of Dual-Target CAR-NK Cells in Relapsed\u002FRefractory Small Cell Lung Cancer (SCLC)","A Phase 1\u002F2 Adaptive Dose-Escalation and Expansion Study of Dual-Targeting Chimeric Antigen Receptor Natural Killer (CAR-NK) Cells Directed Against DLL3, CD56 (NCAM1), and\u002For GD2 in Adults With Relapsed\u002FRefractory Small Cell Lung Cancer","DART-NK-SCLC","Inclusion Criteria:\n\n* Age 18 to 75 years at the time of consent.\n* Histologically or cytologically confirmed small cell lung cancer (SCLC) that is metastatic, extensive-stage, or unresectable, and relapsed or refractory after at least 1 prior systemic regimen (must include a platinum-based regimen unless contraindicated).\n* At least one measurable lesion per RECIST v1.1.\n* ECOG performance status 0 to 1.\n* Adequate organ function (hematologic, renal, hepatic, and cardiac) as defined in the protocol (examples: ANC \\>= 1.0 x10\\^9\u002FL, platelets \\>= 75 x10\\^9\u002FL, creatinine clearance \\>= 50 mL\u002Fmin, AST\u002FALT \\\u003C= 3 x ULN, total bilirubin \\\u003C= 1.5 x ULN).\n* Life expectancy \\>= 12 weeks.\n* Tumor tissue available (archival or fresh) for antigen profiling (DLL3, CD56\u002FNCAM1, GD2).\n* Negative pregnancy test for persons of childbearing potential; agreement to use effective contraception for the protocol-defined duration.\n\nExclusion Criteria:\n\n* Active or uncontrolled CNS metastases or leptomeningeal disease (treated\u002Fstable CNS metastases may be allowed per protocol).\n* Prior treatment with CAR-T, CAR-NK, or other gene-modified cellular therapy within 6 months (or any prior therapy directed against the investigational target antigens if it would confound safety\u002Fefficacy assessment).\n* Allogeneic hematopoietic stem cell transplant within 6 months or active graft-versus-host disease.\n* Active uncontrolled infection, including uncontrolled HIV, active hepatitis B or C with viremia, or active tuberculosis.\n* Clinically significant cardiovascular disease (e.g., recent myocardial infarction within 6 months, uncontrolled arrhythmia, LVEF \\\u003C 45%).\n* Active autoimmune disease requiring systemic immunosuppression; chronic systemic corticosteroid use \\> 10 mg\u002Fday prednisone equivalent (unless for physiologic replacement).\n* Concurrent malignancy requiring active treatment (exceptions may apply for certain non-melanoma skin cancers or in situ cancers).\n* Pregnant or breastfeeding.\n* Any condition that, in the investigator's opinion, would make participation unsafe or interfere with compliance.",{"count":316,"type":20},60,[23,70],"This study is an open-label, multi-center, adaptive Phase 1\u002F2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3\u002FCD56, DLL3\u002FGD2, and CD56\u002FGD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).",[27,320,321],"Relapsed\u002FRefractory SCLC","SCLC, Extensive Stage",[323,324,256,325,326,327,328,329,330,331],"CAR-NK","dual-target","CD56","NCAM1","GD2","adoptive cell therapy","mmunotherapy","solid tumor","small cell lung cance","2026-03-14",{"date":334,"type":52},"2026-03-18",{"date":336,"type":52},"2026-02-02",{"date":338,"type":20},"2028-04-17",{"name":340,"class":59},"Beijing Biotech",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":285,"phases":4,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":142},"100626352","a-real-world-study-evaluating-the-efficacy-and-safety-of-adebrelimab-in-patients-with-advanced-sclc-100626352","NCT07434518","A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC","A Real-world Study on the Efficacy and Safety of Adebrelimab in the Treatment of Advanced-stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer;\n* Age ≥ 18 years;\n* The investigator determines that the patient is eligible for or is already receiving adebrelimab treatment.\n\nExclusion Criteria:\n\n* Patients concurrently receiving other immune-modulating drugs or therapies;\n* Patients currently participating in other interventional studies;\n* Patients with concurrent other malignancies;\n* Patients with missing key study-related data.","100 Years",{"count":350,"type":20},500,"The goal of this observational study is to evaluate the safety and efficacy of adebrelimab in the perioperative and advanced-stage treatment of small cell lung cancer （SCLC） under real-world conditions. The main questions it aims to answer are:\n\n1. The safety of adebrelimab treatment in patients with advanced SCLC under real-world conditions, with a specific focus on the incidence of grade ≥3 immune-related adverse events. Safety monitoring begins when patients start receiving adebrelimab treatment and continues until 90 days after the last dose of adebrelimab.\n2. Observe and evaluate the efficacy of adebrelimab in patients with small cell lung cancer under real-world conditions. This includes overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, the study seeks to further explore the impact of patient baseline characteristics, such as brain metastases or liver metastases, and biomarkers on prognosis.",[27],[354,35,43],"Safety","2026-02-20",{"date":357,"type":52},"2026-02-25",{"date":359,"type":52},"2026-01-27",{"date":361,"type":20},"2028-06-30",{"name":363,"class":82},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",{"id":365,"slug":366,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":371,"targetDuration":4,"studyType":21,"phases":373,"briefSummary":374,"conditions":375,"keywords":376,"overallStatus":381,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":142},"100620519","phase-2-a-study-of-bemotuzumab-plus-chemotherapy-and-anlotinib-induction-followed-by-bemotuzumab-anlotinib-and-consolidative-thoracic-radiotherapy-in-extensive-stage-small-cell-lung-cancer-100620519","NCT07358676","A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","An Exploratory Phase II Study of Bemotuzumab Combined With Chemotherapy and Anlotinib as Induction Therapy, Followed by Bemotuzumab, Anlotinib, and Consolidative Thoracic Radiotherapy in Patients With Extensive-Stage Small Cell Lung Cancer","\\*\\*Inclusion Criteria:\\*\\*\n\n1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) per VALG staging.\n2. No prior systemic therapy for ES-SCLC.\n3. At least one measurable lesion as defined by RECIST 1.1 criteria.\n4. Age 18-75 years.\n5. ECOG performance status of 0-2.\n6. Life expectancy of ≥3 months.\n7. Adequate hematologic and organ function:\n\n   * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL.\n   * Platelet count ≥ 100 × 10\\^9\u002FL.\n   * Hemoglobin ≥ 80 g\u002FL.\n   * Creatinine clearance ≥ 50 mL\u002Fmin.\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN).\n   * AST and ALT ≤ 2.5 × ULN.\n   * Albumin ≥ 28 g\u002FL.\n   * INR and APTT ≤ 1.5 × ULN.\n   * Left ventricular ejection fraction (LVEF) ≥ 50%.\n8. For females of childbearing potential: negative serum pregnancy test within 3 days prior to dosing and agreement to use highly effective contraception.\n9. For males: agreement to use barrier contraception.\n10. Willing and able to provide written informed consent and comply with study procedures.\n\n\\*\\*Exclusion Criteria:\\*\\*\n\n1. Symptomatic brain metastases. (Asymptomatic, treated, and stable brain metastases for ≥1 month without steroids are allowed).\n2. Prior thoracic radiotherapy for SCLC.\n3. Prior treatment with anti-angiogenic agents (e.g., anlotinib, bevacizumab) or anti-PD-1\u002FPD-L1 therapies.\n4. Factors affecting oral medication intake (e.g., inability to swallow, major gastrointestinal resection).\n5. Uncontrolled effusions requiring repeated drainage (pleural, pericardial, or ascites).\n6. Imaging evidence of tumor invasion of major blood vessels or high risk of fatal hemorrhage as judged by the investigator.\n7. History of significant bleeding tendency or coagulopathy, including clinically significant hemoptysis (\\>1 tablespoon daily within 3 months) or significant bleeding within 4 weeks prior to enrollment.\n8. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.\n9. Arterial\u002Fvenous thrombotic events within 6 months prior to enrollment (e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism).\n10. Active autoimmune disease requiring systemic treatment within 2 years prior to first dose.\n11. Any other condition that, in the investigator's judgment, increases risk or renders the patient unsuitable for the study.",{"count":372,"type":20},25,[70],"This is a phase II study evaluating a new combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial phase with the drug Bemotuzumab plus standard chemotherapy and anlotinib, followed by a phase combining Bemotuzumab, anlotinib, and chest radiation. The primary objectives are to assess the efficacy of this approach in delaying cancer growth (progression-free survival) and to evaluate its safety in approximately 25 patients.",[27,321],[27,377,378,379,380],"bemotuzumab","anlotinib","hypofractionated radiotherapy","Induction therapy","NOT_YET_RECRUITING","2026-01-14",{"date":384,"type":52},"2026-01-22",{"date":386,"type":20},"2026-02-01",{"date":388,"type":20},"2028-01-01",{"name":390,"class":82},"Tianjin Medical University Cancer Institute and Hospital",{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":401,"conditions":402,"keywords":407,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":418},"100476939","phase-1-jab-2485-activity-in-adult-patients-with-advanced-solid-tumors-100476939","NCT05490472","JAB-2485 Activity in Adult Patients With Advanced Solid Tumors","A Phase 1\u002F2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Must be able to provide an archived tumor sample\n* Must have histologically or cytologically confirmed metastatic or locally advanced solid tumor\n\n  * Dose Expansion phase cohorts must meet specific expression or gene mutation where indicated\n* Must be refractory to or become intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n* Must have at least 1 measurable lesion per RECIST v1.1\n* Must have adequate organ functions\n* Must be able to swallow and retain orally administered medication\n\nExclusion Criteria:\n\n* Has central nervous system (CNS) metastases or carcinomatous meningitis, except if CNS metastases treated and no evidence of radiographic progression or hemorrhage for at least 28 days\n* Active infection requiring systemic treatment within 7 days\n* Active hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV\n* Any severe and\u002For uncontrolled medical conditions\n* left ventricular ejection fraction (LVEF) ≤50% assessed by echocardiogram (ECHO) or multigated acquisition scan (MUGA)\n* QT interval using Fridericia's formula (QTcF) interval \\>470 msec\n* Experiencing unresolved CTCAE 5.0 Grade \\>1 toxicities\n* Clinically significant eye disorders",{"count":399,"type":20},102,[23,70],"This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.",[167,403,404,405,406],"ER+ Breast Cancer","Triple Negative Breast Cancer, TNBC","ARID1A Gene Mutation","Small Cell Lung Cancer, SCLC",[408,405],"Aurora A inhibitor","2026-01-07",{"date":411,"type":52},"2026-01-09",{"date":413,"type":52},"2022-12-20",{"date":415,"type":20},"2027-08",{"name":417,"class":59},"Jacobio Pharmaceuticals Co., Ltd.",8,{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":21,"phases":428,"briefSummary":429,"conditions":430,"keywords":435,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":457},"100489405","phase-1-a-study-of-peluntamig-pt217-in-patients-with-neuroendocrine-carcinomas-expressing-dll3-the-skybridge-study-100489405","NCT05652686","A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1\u002F2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and\u002For Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)","Key Inclusion Criteria\n\n1. NECs that have transformed from NSCLC are not eligible. Part A: Patients with histologically or cytologically confirmed unresectable advanced or metastatic small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), or extrapulmonary neuroendocrine carcinoma (EP-NEC). Patients with tumors that are of mixed histology are eligible only if neuroendocrine carcinoma\u002Fsmall cell cancer component is predominant and represents at least 50% of the overall tumor tissue. Patients with well differentiated grade 3 neuroendocrine tumors (Ki-67 ≥ 55%) may be considered if their tumors are DLL3 positive.\n\n   Patients may have progressed after standard of care treatments (at least one line of platinum-based chemotherapy with or without immune checkpoint inhibitor for SCLC patients) or other treatment options, or for whom treatment is not available or not tolerated.\n\n   Part B: Patients must meet the same criteria in Part A, C or D.\n\n   Part C:\n\n   • Cohort C1: patients with LCNEC or EP-NEC eligible for first-line (1L) CE treatment. SCLC patients who have relapsed on a 1L treatment (including platinum-based therapy with or without ICI) but remain platinum sensitive (defined as patients who experienced disease progression at least 90 days after their last platinum based chemotherapy) and are eligible for CE treatment rechallenge.\n\n   Cohort C2: patients with SCLC, LCNEC and EP-NEC eligible for second line (2L) paclitaxel treatment.\n\n   Part D:\n   * Cohort D1: will include 2L patients with SCLC, LCNEC, pr EP-NEC that have progressed\u002Frelapsed from their first-line treatment that may have included an ICI.\n   * Cohort D2: will include 1L ES-SCLC patients that have completed their induction therapy with carboplatin and etoposide plus atezolizumab and are eligible to continue with atezolizumab. These patients must have either stable disease or partial response prior to enrollment.\n   * Cohort D3: will include 1L ES-SCLC patients that are treatment naïve or have received C1D1\u002F2\u002F3 and are eligible for treatment with CE plus atezolizumab.\n2. Able to provide a formalin fixed, paraffin embedded (FFPE) tumor tissue sample (preferably a newly acquired biopsy, or if not possible, archival tissue) to be assessed for DLL3 expression and other biomarkers.\n3. ECOG performance status of 0 or 1.\n4. Adequate organ function confirmed at screening and within 72 hours of initiating C1D1 of Peluntamig (PT217) treatment.\n\nKey Exclusion Criteria\n\n1. Women who are pregnant or lactating.\n2. Women of child-bearing potential (WOCBP) who do not use adequate birth control.\n3. Autoimmune disease requiring systemic treatment within the past twelve months.\n4. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and IL-2, and excluding ICIs) within 4 weeks or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment with Peluntamig (PT217).\n5. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications (≥ 10 mg prednisone, or equivalent) within 14 days prior to study drug Peluntamig (PT217), or anticipation of need for systemic immunosuppressive medication during study drug Peluntamig (PT217).\n6. Patients who have experienced Grade ≥ 3 immune-related events, such as (non-infectious) pneumonitis, interstitial lung disease, myocarditis.\n7. Treatment with therapeutic oral or i.v. antibiotics within 2 weeks prior to initiation of study treatment with Peluntamig (PT217).\n8. Patients with untreated brain or central nervous system (CNS) metastases or brain\u002FCNS metastases that have progressed.\n\n   Note: Patients with treated brain metastases that are off corticosteroids and have been clinically stable for 14 days are eligible for treatment.\n9. Impaired cardiac function or significant diseases.\n10. For Part D only, uncontrolled hypercalcemia.\n11. For Part D only, significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.\n12. Prior hemolytic anemia or Evans Syndrome in the last 3 months.\n13. Patients who have Grade ≥ 3 neuropathy.\n14. Patients who are currently receiving treatment with therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants .\n\nAdditional criteria may apply.",{"count":427,"type":20},203,[23,70],"This is a first-in-human, Phase 1\u002F2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.",[27,431,432,433,434,247],"Large Cell Neuroendocrine Cancer (LCNEC)","Neuroendocrine Prostate Cancer (NEPC)","Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","Neuroendocrine Carcinomas (NEC)",[256,436,437,43,438,439,440,441,442,443,444,445,446,261,447],"DLL3 expressing tumors","Lung cancer","LCNEC","NEPC","GEP-NEC","Small Cell Lung Cancer","Large cell neuroendocrine cancer","Neuroendocrine prostate cancer","Gastroenteropancreatic neuroendocrine carcinoma","Neuroendocrine carcinoma","Extrapulmonary neuroendocrine carcinoma","CD47","2025-09-18",{"date":450,"type":52},"2025-09-23",{"date":452,"type":52},"2023-09-05",{"date":454,"type":20},"2028-08",{"name":456,"class":59},"Phanes Therapeutics",12,{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":465,"targetDuration":4,"studyType":21,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":381,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":142},"100600893","phase-2-a-study-evaluating-concurrent-chemoradiotherapy-combined-with-dual-immune-checkpoint-blockade-for-limited-stage-small-cell-lung-cancer-100600893","NCT07103408","A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer","A Phase II Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade (PD-1\u002FCTLA-4) for Limited-stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* Males or females aged 18 to 75 years or older;\n* Patients must have histologically or cytologically confirmed small cell lung cancer (SCLC);\n* Stage II-III according to AJCC 8th staging system;\n* No prior chemotherapy, radiotherapy, surgery, targeted therapy, or immunotherapy;\n* Expected survival ≥ 12 weeks;\n* WHO Performance Status (PS) score of 0 or 1;\n* Female subjects must not be breastfeeding;\n* Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment and for 5 months after the last dose of study drug (i.e., 30 days \\[one ovulation cycle\\] plus approximately five half-lives of the study drug);\n* Adequate organ and bone marrow function as defined by the following criteria:\n* Forced Expiratory Volume in 1 second (FEV1) ≥ 800 mL;\n* Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL;\n* Platelets ≥ 100 × 10⁹\u002FL;\n* Hemoglobin ≥ 9.0 g\u002FdL;\n* Creatinine clearance ≥ 50 mL\u002Fmin as calculated by the Cockcroft-Gault formula (Cockcroft and Gault, 1976);\n* Serum bilirubin ≤ 1.5 × upper limit of normal (ULN);\n* AST and ALT ≤ 2.5 × ULN.\n\nExclusion Criteria:\n\n* Concurrent enrolment in another clinical study, unless it is an observational(non-interventional) clinical study;\n* Mixed small cell and non-small cell lung cancer histology;\n* Prior use of anti-PD-1, anti-PD-L1, or anti-CTLA4 antibodies;\n* Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access;\n* Active or prior documented autoimmune disease within the past 2 years;\n* Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative colitis);\n* History of primary immunodeficiency;\n* History of organ transplant that requires therapeutic immunosuppression;\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active bleeding diatheses including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent;\n* Known history of tuberculosis;\n* History of another primary malignancy within 5 years prior to starting treatment, except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the disease under study;\n* Female patients who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control.",{"count":466,"type":20},56,[70],"This study will enroll patients with limited-stage small cell lung cancer (SCLC). Patients will receive chemotherapy (etoposide and platinum-based drugs) combined with dual immune checkpoint blockade (PD-1\u002FCTLA-4) and thymosin alpha 1, with a total cycles of 4. Thoracic radiotherapy was performed no later than the three cycle of chemotherapy. Prophylactic cranial irradiation was recommended for patients who received complete response or partial response after chemoradiotherapy. Finally consolidation therapy with dual immune checkpoint blockade (PD-1\u002FCTLA-4) and thymosin alpha 1 was conducted for one year. The study aims to evaluate the efficacy and safety of this treatment regimen.",[470],"Small-Cell Lung Cancer (SCLC)","2025-08-02",{"date":473,"type":52},"2025-08-05",{"date":475,"type":20},"2025-10-01",{"date":477,"type":20},"2029-09-30",{"name":479,"class":82},"Sun Yat-sen University",{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":487,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":492,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":499,"completionDateStruct":500,"leadSponsor":502,"locationsCount":142},"100553396","phase-2-neoadjuvant-adebrelimab-in-resectable-sclc-a-randomized-trial-100553396","NCT06485544","Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial","A Multicenter Randomized Controlled Trial of Neoadjuvant Adebrelimab Combined With Chemotherapy for Resectable Small Cell Lung Cancer (SCLC)","Inclusion Criteria:\n\n1. Age between 18 and 75 years, inclusive, with no restriction on gender.\n2. ECOG performance status of 0-1.\n3. Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC).\n4. According to the 8th edition of AJCC staging, participants must have resectable or potentially resectable stage I-IIIB (T1-4N0-2M0) SCLC.\n5. Measurable lesions (tumor lesions with a CT scan long axis ≥10 mm, lymph node lesions with a CT scan short axis ≥10 mm).\n6. Initial diagnosis of small cell lung cancer without prior treatment with radiation, chemotherapy, traditional Chinese medicine, surgery, or targeted therapy.\n7. Various imaging examinations including PET-CT, enhanced CT or ultrasound of the chest and abdomen, MRI of the head, and bone scan confirm no metastatic lesions.\n8. Participants must have sufficient cardiopulmonary function to tolerate planned lung resection surgery.\n9. No contraindications to immune checkpoint inhibitor (ICI) use based on laboratory tests.\n10. Normal organ function, as defined by the following criteria:\n\n(1) Hematological criteria (within 14 days without blood transfusion, hematopoietic factors, or correcting medications):\n\n1. ANC ≥ 1.5 × 10\\^9\u002FL;\n2. PLT ≥ 100 × 10\\^9\u002FL;\n3. Hb ≥ 90 g\u002FL; (2) Biochemical criteria:\n\na. TBIL ≤ 1.5 × ULN; b. ALT, AST ≤ 2.5 × ULN (if abnormal liver function due to liver metastasis, ≤ 5 × ULN); c. Serum creatinine (sCr) ≤ 1.5 × ULN, estimated glomerular filtration rate (eGFR) ≥ 50 mL\u002Fmin (Cockcroft-Gault formula); (3) Coagulation function: INR ≤ 1.5 × ULN and APTT ≤ 1.5 × ULN. 11. Female participants of childbearing potential must have a negative serum pregnancy test within 3 days before starting study medication and agree to use a medically accepted method of highly effective contraception during the study and for 3 months after the last dose of study drug (e.g., intrauterine device, contraceptive pills, or condoms). Male participants with female partners of childbearing potential must have undergone surgical sterilization or agree to use effective contraception during the study and for 3 months after the last dose of study drug.\n\n12\\. Participants must voluntarily consent to participate in this study, sign an informed consent form, demonstrate good compliance, and agree to follow-up visits.\n\nExclusion Criteria:\n\n1. Central nervous system metastasis.\n2. History of any active autoimmune disease or autoimmune disease (including but not limited to moderate or severe interstitial lung disease, uveitis, colitis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism \\[patients controlled by hormone replacement therapy may be included\\]); patients with vitiligo or childhood asthma completely resolved without adult intervention may be included; patients requiring bronchodilators for medical intervention are excluded.\n3. Congenital or acquired immunodeficiency, such as HIV infection, active hepatitis B (HBV DNA ≥ 500 IU\u002FmL), hepatitis C (HCV antibody positive with HCV-RNA above the lower limit of detection by analytical methods), or co-infection of hepatitis B and C, active pulmonary tuberculosis.\n4. Use of immunosuppressive drugs within 14 days prior to the first administration of the study drug, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroid hormones (i.e., no more than 10 mg\u002Fday of prednisone or its equivalent).\n5. Vaccination with live attenuated vaccines within 4 weeks before the first administration or planned during the study period.\n6. Any other malignancy within the past 3 years.\n7. Evidence of past or present pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced pneumonia, or severely impaired lung function.\n8. Uncontrolled hypertension.\n9. Grade II or higher myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QTc interval ≥450 ms for males and ≥470 ms for females). According to NYHA standards, Class III-IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C 50% by cardiac ultrasound, myocardial infarction within 6 months before enrollment, NYHA Class II or higher heart failure, uncontrolled angina, uncontrolled severe ventricular arrhythmias, clinically significant pericardial disease, or electrocardiogram (ECG) indicating acute ischemia or active conduction system abnormalities.\n10. Severe infection within 4 weeks before the first administration (e.g., requiring intravenous antibiotics, antifungals, or antivirals), or unexplained fever \\> 38.5°C during screening\u002Ffirst administration.\n11. History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n12. Pregnant or breastfeeding women; patients of childbearing potential unwilling or unable to use effective contraception.\n13. Known allergic reaction, hypersensitivity, or intolerance to SHR-1316, etoposide, cisplatin, or their excipients.\n14. Participation in another clinical study or less than 4 weeks since the end (last dose) of a previous clinical study, or less than 5 half-lives of the study drug.\n15. Known history of substance abuse, alcohol abuse, or drug addiction.\n16. Any condition that the investigator believes may compromise the safety of the participant or the participant's ability to meet or follow study requirements.",{"count":488,"type":20},104,[70],"This study is a randomized, open-label, multicenter exploratory research aiming to evaluate the efficacy and safety of Adebrelimab in combination with chemotherapy (etoposide and platinum-based therapy) as neoadjuvant treatment for resectable stage I-IIIB (stage IIIB limited to T1-4N1-2M0) small cell lung cancer (SCLC). The study is primarily conducted at Tangdu Hospital of the Fourth Military Medical University. A total of 104 patients with stage IA-IIIB SCLC (stage IIIB limited to T1-4N1-2M0) will be enrolled and randomized 1:1 to receive either Adebrelimab plus chemotherapy or chemotherapy alone. Each patient will undergo 3 cycles of study treatment followed by a 3-4 week break before surgery. Treatment will be discontinued if patients experience disease progression, intolerable drug-related adverse events, withdrawal of informed consent, or other specified conditions during the study. Effectiveness and safety outcomes will be monitored throughout the trial. The primary objective is to evaluate pathological complete response (pCR) with Adebrelimab combination therapy. Secondary objectives include assessing event-free survival (EFS), major pathological response (mPR), objective response rate (ORR), disease-free survival (DFS), and safety.",[27],[43,493,494,495],"Adebrelimab","Neoadjuvant","Chemotherapy","2024-07-01",{"date":498,"type":52},"2024-07-03",{"date":496,"type":20},{"date":501,"type":20},"2026-12-30",{"name":503,"class":82},"Tang-Du Hospital"]